Key result
Urgent/emergent transcatheter mitral valve repair in high-risk patients with heart failure or cardiogenic shock resulted in 21% 30-day mortality and 50% mortality over a median 153 days.
Why the study?
TMVr is used for select patients with severe mitral regurgitation, but knowledge regarding outcomes for urgent/emergent TMVr is limited.
Population
20 patients undergoing urgent/emergent TMVr using MitraClip
Comparison
Survivors vs nonsurvivors
Design
Single-center retrospective chart review
Follow-up
Median 153 days (IQR 20-491)
Authors
Loading...
Urgent/emergent TMVr was associated with high short-term mortality in shock or decompensated HF; leaves open optimal selection and periprocedural management for prospective trials.
Observational (n=20)
No
Urgent/emergent TMVr in high-risk patients with ADHF or cardiogenic shock is associated with high short-term mortality and periprocedural complications, highlighting the need for careful patient selection.
Kovach et al. (2020) conducted an observational in Severe mitral regurgitation with acute decompensated heart failure or cardiogenic shock (n=20). Urgent/emergent transcatheter edge-to-edge mitral valve repair (TMVr) was evaluated on 30-day mortality. Urgent/emergent transcatheter mitral valve repair in high-risk patients with heart failure or cardiogenic shock resulted in 21% 30-day mortality and 50% mortality over a median 153 days.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: